Altamira Therapeutics Ltd (CYTOF)
Altamira Therapeutics Ltd. is a common stock listing of a healthcare company focused on preclinical-stage biopharmaceutical research and development. The company works in Switzerland, Australia, the United States, and Europe, and is based in Hamilton, Bermuda. Its programs include peptide-based nanoparticle technology for RNA delivery to extrahepatic tissues through the xPhore platform, as well as Bentrio, a drug-free nasal spray designed for protection against airborne viruses and allergens. Altamira is also advancing AM-401 for KRAS-driven cancer, AM-411 for rheumatoid arthritis, and AM-125, which has reached the post-phase II stage for intranasal treatment of vertigo. The company was previously known as Auris Medical Holding Ltd. and adopted its current name in July 2021.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-CYTO.F
|
Not available
|
Not available
|
Not available
|
Fair
|
0.0%
|
0.1x
|
571.547 K
|
1.215 M
|
64.8%
|
-21.0
|
77.8%
|
